Every Form 4 that Alumis Inc (ALMS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALMS filings page.
ALUMIS INC. (ALMS) director Srinivas Akkaraju, through affiliated funds, reported both purchases and sales of Alumis common stock in early September 2026, with overall net buying activity. On September 8, 2026, Samsara BioCapital, L.P. sold 48,066 shares at a weighted average of $10.5484 and purchased 273,291 shares at a weighted average of $10.6271; Samsara Opportunity Fund, L.P. sold 48,065 shares and purchased 273,290 shares at the same respective weighted average prices.
On September 4, 2026, each of Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. separately purchased 220,070 shares at a weighted average price of $11.1730. A holding line shows 3,553 shares held directly. A footnote states that the September 8, 2026 sales and purchases were matchable under Section 16(b), creating short-swing profit liability, and that the reporting person agreed to disgorge the short-swing profit to Alumis, less transaction costs. Another footnote explains that prices are weighted averages over disclosed intraday price ranges, and that the reporting person disclaims beneficial ownership of fund-held shares except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is indicated.
Alumis Inc. Chief Financial Officer John R. Schroer reported the sale of 3,282 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share, in multiple trades between $25.56 and $26.42. According to the disclosure, the sale was a mandatory sell-to-cover transaction to satisfy tax obligations from the vesting and settlement of restricted stock units granted on July 29, 2025, and was not a discretionary trade. After these transactions, he directly owns 24,718 shares of Alumis common stock.
Alumis Inc. Chief Legal Officer Sanam Pangali reported the sale of 1,364 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share. According to the company policy, this was a mandatory sell-to-cover transaction to satisfy tax obligations from vesting restricted stock units and did not represent a discretionary sale. After the sale, Pangali held 9,747 shares of Alumis common stock directly.
Alumis Inc. executive Roy C. Hardiman, Chief Business & Strategy Officer, reported selling 2,692 shares of Common Stock on August 3, 2026 at a weighted average price of $26.37 per share. The sale was effected under the company’s policy requiring sell-to-cover transactions to satisfy tax obligations from the vesting and settlement of restricted stock units granted on July 29, 2025 and, according to the disclosure, does not represent a discretionary sale. After this transaction, he holds 207,746 shares directly, including 1,037 shares acquired on November 20, 2025 and 3,000 shares acquired on May 20, 2026 under the 2024 Employee Stock Purchase Plan, and 6,417 shares are held indirectly by his daughter residing in his primary residence.
Alumis Inc. Chief Scientific Officer David M. Goldstein reported selling 2,596 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share. The sale was required under company policy to sell-to-cover tax obligations from vesting restricted stock units granted on July 29, 2025 and is described as non-discretionary. After the sale, he directly held 30,970 shares, including 2,177 shares acquired on May 20, 2026 under the 2024 Employee Stock Purchase Plan, plus additional indirect holdings through a family trust and family members.
ALUMIS INC.’s Chief Medical Officer, Jorn Drappa, reported a mandatory sale of 2,447 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share, in multiple trades between $25.54 and $26.42. The sale was executed under company policy as a sell-to-cover transaction to satisfy tax obligations arising from the vesting and settlement of restricted stock units granted on July 29, 2025, and is described as not a discretionary sale. Following these sales, Drappa directly holds 56,892 shares of Alumis common stock.
ALUMIS INC. Chief Development Officer Bradley Mark Christopher sold 2,572 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share in a sell-to-cover transaction to satisfy tax obligations from restricted stock unit vesting, and the sale is described as non-discretionary. The shares were sold in multiple transactions at prices ranging from $25.60 to $26.42. After this sale, he directly holds 48,533 shares, including 2,377 shares acquired on May 20, 2026 under the 2024 Employee Stock Purchase Plan. He also serves as trustee for two 2025 GRATs that hold shares, each receiving 20,026 shares transferred from related 2023 GRATs on October 30, 2025.
ALUMIS INC. Chief Legal Officer Sanam Pangali exercised stock options for 5,000 shares of common stock at $5.06 per share and sold 5,000 shares in an open-market transaction at $28.00 per share on July 6, 2026.
Following these transactions, Pangali directly owns 11,111 shares of Alumis common stock. The exercised options were granted under the company’s 2024 Equity Incentive Plan, with vesting tied to the executive’s continued service.
ALUMIS INC. director Lynn A. Tetrault reported receiving new equity awards consisting of restricted stock units and stock options. The filing shows a grant of 3,553 shares of common stock through RSUs at no cash cost and a stock option covering 15,528 shares with a fixed exercise price of $28.14 per share.
Both the RSUs and the option are scheduled to vest on the first anniversary of the grant date, and in any event will be fully vested by the issuer’s 2027 annual stockholder meeting, subject to her continuous service under the company’s 2024 Equity Incentive Plan. The awards will also vest in full upon a qualifying change in control if continuous service is maintained through that date.
ALUMIS INC. director Yao Zhengbin reported equity compensation grants, acquiring both restricted stock units and stock options rather than making any open‑market trades. He received 3,553 shares of Common Stock as a restricted stock unit (RSU) award at no cash cost.
He also received a stock option covering 15,528 shares of Common Stock at an exercise price of $28.14 per share, expiring on June 29, 2036. After the grants, he directly holds 27,082 Common shares. Both the RSUs and options vest on the first anniversary of the grant date, and will in any case be fully vested by the issuer’s 2027 annual stockholder meeting, with accelerated vesting upon a qualifying Change in Control, all subject to his continuous service under the company’s 2024 Equity Incentive Plan.
ALUMIS INC. director Sapna Srivastava received equity-based compensation in the form of restricted stock units and stock options. She was granted 3,553 shares of common stock issuable upon settlement of RSUs and an option covering 15,528 shares of common stock at an exercise price of $28.14 per share.
Both the RSUs and the option shares vest on the first anniversary of the grant date, and in any case will be fully vested on the date of the issuer's 2027 annual stockholder meeting, subject to her continuous service under the company’s 2024 Equity Incentive Plan. They will also vest in full upon a Change in Control, again subject to continuous service.
ALUMIS INC. director Patrick Machado reported new equity awards and his updated holdings. He received a grant of 3,553 shares of common stock as a restricted stock unit (RSU) award at no cost, which will vest on the first anniversary of the grant date or, in any case, by the company’s 2027 annual stockholder meeting, subject to continuous service or earlier vesting upon a Change in Control under the 2024 Equity Incentive Plan. He was also granted stock options for 15,528 shares of common stock at an exercise price of $28.14 per share, with the same vesting conditions. Following these awards, he holds 3,553 common shares directly and 7,064 common shares indirectly through the Patrick Machado Revocable Trust, where he serves as trustee, plus the newly granted options.
Alumis Inc. director Srinivas Akkaraju reported new equity awards and updated fund holdings. He received a grant of 3,553 shares of common stock in the form of restricted stock units, plus stock options covering 15,528 shares at an exercise price of $28.14 per share. Both the RSUs and options vest on the first anniversary of the grant date, and in any event are fully vested by the issuer's 2027 annual stockholder meeting, subject to his continuous service and with full vesting upon a qualifying change in control.
After these grants, he directly holds 3,553 shares and options on 15,528 shares, and is associated with indirect holdings of 1,853,488 shares through Samsara Opportunity Fund, L.P. and 4,491,731 shares through Samsara BioCapital, L.P. The fund positions are held by those partnerships, with Akkaraju’s beneficial interest limited to his pecuniary stake.
Alumis Inc. Chief Medical Officer Jorn Drappa exercised stock options to acquire 26,852 shares of common stock. The Form 4 shows two option exercises on May 22, 2026, covering 15,535 shares at an exercise price of $5.06 per share and 11,317 shares at $8.84 per share. All transactions are coded as exercises of derivative securities, with no open-market purchases or sales reported in this filing.
ALUMIS INC. insider filing shows internal share transfers among Foresite-affiliated entities, not market trades. Foresite Labs Affiliates 2021, LLC and Foresite Labs, LLC reported Form 4 transactions coded "J" in Common Stock on April 1, 2026, described as other acquisitions or dispositions.
Footnotes explain these were pro rata, in-kind distributions without additional consideration under Exchange Act Rules 16a-13 and 16a-9, rather than purchases or sales. Shares were distributed between entities such as Foresite Labs Affiliates 2021, LLC, Foresite Labs, LLC, and TFL Investment Holdings, LLC, with various Foresite funds and co-invest vehicles holding record ownership.
The reporting persons and related entities note that voting and dispositive power over the shares may be attributed to managing LLCs and to James B. Tananbaum in his roles, while explicitly disclaiming group status and beneficial ownership beyond any pecuniary interest.
ALUMIS INC. reported a Form 4 showing internal equity restructurings by entities associated with Foresite Capital and Foresite Labs, rather than open-market trading. On April 1, 2026, several J-code transactions moved blocks of common stock through pro rata, in-kind distributions for no cash consideration.
Labs Affiliates made in-kind distributions of shares to its members, including Foresite Labs, LLC, which then distributed shares on a pro rata basis to its own members, such as TFL Investment Holdings, LLC. Additional indirect holdings are reported for Foresite Capital Fund V, Opportunity Fund V, Fund VI, Labs Co-Invest V and Foresite Labs Fund I, all with voting and dispositive power described in the footnotes and subject to customary beneficial ownership disclaimers.
ALUMIS INC. director and 10% owner James B. Tananbaum reported a series of internal restructurings of 4,103,630 shares of common stock, coded as "J" transactions. The shares moved through pro rata, in-kind distributions among affiliated entities for no consideration and not as open-market purchases or sales.
The filing shows indirect holdings across several Foresite and Labs-related funds and LLCs, with post-transaction positions such as 5,702,536, 2,908,332, 4,247,670, 194,459 and 1,960,337 shares held of record by these entities. Tananbaum may share voting and dispositive power but consistently disclaims group status and beneficial ownership beyond his pecuniary interest.
Alumis Inc. reported that Chief Legal Officer Sanam Pangali received a stock option grant for 186,200 shares of common stock at an exercise price of $26.31 per share on January 26, 2026. These options give the right to buy Alumis shares at that price in the future.
According to the vesting terms, 25% of the shares underlying the option vest on January 26, 2027. The remaining shares then vest in equal monthly installments over the following 36 months, as long as the executive maintains Continuous Service under the company’s 2024 Equity Incentive Plan, with potential acceleration as provided in the plan.
Alumis Inc. reported that President, CEO and Chairman Martin Babler received a new stock option grant. On January 26, 2026, he was awarded an option to buy 745,875 shares of Alumis common stock at an exercise price of $26.31 per share, expiring January 25, 2036.
According to the vesting terms, 25% of the shares underlying this option vest on January 26, 2027. The remaining shares then vest in equal monthly installments over the following 36 months, contingent on his continuous service to Alumis and subject to possible acceleration under the company’s 2024 Equity Incentive Plan.
Alumis Inc. reported a stock option grant to Chief Business & Strategy Officer Roy C. Hardiman. On January 26, 2026, he was awarded a stock option covering 190,875 shares of common stock at an exercise price of $26.31 per share.
According to the filing, 25% of the shares underlying this option vest on January 26, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. The option expires on January 25, 2036, and all 190,875 derivative securities are reported as directly owned.
Alumis Inc. reported that Chief Development Officer Bradley Mark Christopher received a stock option grant on January 26, 2026. The option covers 190,225 shares of common stock at an exercise price of $26.31 per share and is held directly.
According to the vesting terms, 25% of the shares underlying the option vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on his continuous service under the company’s 2024 Equity Incentive Plan.
Alumis Inc. reported that Chief Medical Officer Jorn Drappa received a new stock option grant. The option covers 221,450 shares of common stock at an exercise price of $26.31 per share, awarded on January 26, 2026.
According to the vesting terms, 25% of the shares vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on Drappa’s continuous service under the company’s 2024 Equity Incentive Plan and subject to potential acceleration provisions.
Alumis Inc. (ALMS) reported an equity award to its Chief Financial Officer, John R. Schroer. On January 26, 2026, he was granted a stock option covering 202,225 shares of common stock at an exercise price of $26.31 per share.
These options vest over time: 25% of the underlying shares vest on January 26, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months. Vesting is conditioned on his continued service to Alumis under the company’s 2024 Equity Incentive Plan.
Alumis Inc. reported a stock option grant to Chief Scientific Officer David M. Goldstein. On January 26, 2026, he received an option to buy 216,675 shares of common stock at an exercise price of $26.31 per share, held as a direct derivative position.
According to the vesting terms, 25% of the shares underlying this option vest on January 26, 2027. The remaining shares vest in equal monthly installments over the following 36 months, contingent on his continued service under the company’s 2024 Equity Incentive Plan.
Alumis Inc. director Srinivas Akkaraju reported an indirect purchase of Alumis common stock tied to investment entities he is associated with. On January 9, 2026, Samsara Opportunity Fund, L.P. acquired 588,235 shares of Alumis common stock at $17 per share, reported with transaction code "P." After this trade, Samsara Opportunity Fund, L.P. was shown as holding 1,853,488 shares of Alumis indirectly for the reporting person.
The filing also notes an additional 4,491,731 shares of Alumis common stock held indirectly through Samsara BioCapital, L.P. Akkaraju is a managing member or has voting and investment power in the related general partners and may be deemed to beneficially own these holdings, but he disclaims beneficial ownership except to the extent of his pecuniary interest.
Alumis Inc. reported insider activity by investment entities affiliated with Foresite Labs and related funds. On 01/08/2026, these entities executed open‑market purchases of Alumis common stock, including 117,647 shares at $17 per share and a separate purchase of 294,117 shares at $17 per share. After these trades, the reporting structures show indirect beneficial ownership positions such as 5,702,536 shares and 2,908,332 shares in specific funds, along with additional indirect holdings in other affiliated vehicles. The reporting persons, Foresite Labs, LLC and Foresite Labs Affiliates 2021, LLC, are identified as more than 10% owners, and the footnotes explain that the shares are held through various Foresite Capital and Foresite Labs entities with beneficial ownership disclaimed except for each party’s pecuniary interest.
Alumis Inc. (ALMS) received a Form 4 filing from several Foresite Capital and Foresite Labs investment entities that are 10% owners, reporting indirect ownership of Alumis common stock.
On January 8, 2026, Foresite Capital Fund V, L.P. purchased 117,647 Alumis common shares at $17 per share, bringing its indirectly reported holdings to 5,702,536 shares. On the same date, Foresite Capital Opportunity Fund V, L.P. purchased 294,117 shares at $17 per share, with indirectly reported holdings of 2,908,332 shares.
The filing also lists additional indirect common stock holdings: Foresite Capital Fund VI, L.P. with 4,247,670 shares, Labs Co-Invest V, LLC with 194,459 shares, Foresite Labs Fund I, L.P. with 1,960,337 shares, and Foresite Labs Affiliates 2021, LLC with 1,176,470 shares. The reporting entities note that they may be deemed to have voting and dispositive power through their general partners or managing members and each disclaims group status and beneficial ownership beyond its pecuniary interest.
Alumis Inc. director and 10% owner James B. Tananbaum filed a Form 4 reporting indirect ownership changes through investment entities. On January 8, 2026, entities associated with him purchased 117,647 and 294,117 shares of Alumis common stock at $17 per share, reported as indirect acquisitions. The filing also lists sizable indirect holdings in Alumis common stock by multiple Foresite Capital and Foresite Labs funds and LLCs, including Foresite Capital Fund V, Foresite Capital Opportunity Fund V, Foresite Capital Fund VI, Labs Co-Invest V, Foresite Labs Fund I and Foresite Labs Affiliates 2021. The footnotes state that these entities hold the shares of record and that Tananbaum may be deemed to share or have voting and dispositive power, while he disclaims beneficial ownership except for his pecuniary interest.
Alumis Inc. (ALMS) disclosed an insider stock purchase on a Form 4. Investment entities affiliated with Foresite Capital, managed by James B. Tananbaum, reported buying 72,212 shares of Alumis common stock on 11/21/2025 in an open-market transaction coded "P" at a price of $7.38 per share.
After this trade, one reporting entity, Foresite Capital Opportunity Fund V, L.P., is shown as indirectly beneficially owning 2,614,215 shares of Alumis common stock, with additional indirect holdings reported through other Foresite-managed funds. The reporting persons state that each investment vehicle and manager disclaims being part of a group and disclaims beneficial ownership of shares held by the other funds beyond their economic interest.
Alumis Inc. (ALMS) insider James B. Tananbaum, a director and 10% owner, reported buying additional common stock through affiliated investment entities. On 11/21/2025, an indirect account purchased 72,212 Alumis common shares at a price of $7.38 per share, reported as an acquisition. After this transaction, multiple affiliated Foresite Capital and Foresite Labs funds and vehicles are shown as beneficially owning various blocks of Alumis stock, all reported as indirect ownership.
The filing explains that several limited partnerships and LLCs, including Foresite Capital Opportunity Fund V, Foresite Capital Fund V and VI, and multiple Foresite Labs vehicles, hold the shares of record. Management entities and Mr. Tananbaum may be deemed to have voting and dispositive power over these holdings, but he formally disclaims group status and beneficial ownership beyond his pecuniary interest in each entity.
Alumis Inc. (ALMS) reported an insider purchase by a director-affiliated entity. On 11/21/2025, a reporting person bought 72,212 shares of common stock at $7.38 per share, recorded as an indirect holding.
After this transaction, the reporting person reports indirect beneficial ownership of multiple large Alumis positions through affiliated Foresite investment vehicles. These include 2,614,215 shares held by Foresite Capital Opportunity Fund V, L.P., 4,247,670 shares held by Foresite Capital Fund VI, L.P., 5,584,889 shares held by Foresite Capital Fund V, L.P., and additional blocks of 194,459, 1,960,337, and 1,176,470 shares held by other Foresite-related entities.
The filing notes that the various Foresite funds and management entities, including James B. Tananbaum, may be deemed to share voting and dispositive power over these shares but each disclaims being part of a "group" and disclaims beneficial ownership beyond their pecuniary interests.
Alumis Inc. (ALMS) reported an insider share purchase on a Form 4 by a director associated with Samsara investment entities. On 11/20/2025, the reporting person, through Samsara Opportunity Fund, L.P., purchased 125,743 shares of common stock in an open-market transaction at a weighted average price of $7.20 per share, with individual trades occurring between $6.92 and $7.48. Following this transaction, Samsara Opportunity Fund, L.P. was shown as holding 643,260 shares indirectly attributed to the reporting person, and Samsara BioCapital, L.P. was shown as holding an additional 4,491,731 shares indirectly. The reporting person indicates that beneficial ownership of these positions is disclaimed except to the extent of any pecuniary interest.
Alumis Inc. (ALMS) reported insider share purchases by a director affiliated with Foresite entities. On 11/17/2025, the reporting person acquired 50,000 shares of common stock at $5.60 and 150,000 shares at $5.59. On 11/18/2025, a further 117,374 shares were purchased at $6.19, followed by 190,500 shares at $6.56 on 11/19/2025, all reported as indirect ownership.
After these transactions, the Form 4 shows 2,542,003 Alumis shares beneficially owned indirectly under footnote (1), with additional indirect beneficial holdings of 4,247,670, 5,584,889, 194,459, 1,960,337 and 1,176,470 shares through various Foresite Capital and Foresite Labs funds and entities, each with specified control structures and standard beneficial ownership disclaimers.
Alumis Inc. (ALMS) received a series of insider share purchases by Foresite-affiliated funds and entities whose managing member, James B. Tananbaum, serves as a director of the company. Between 11/17/2025 and 11/19/2025, these reporting persons purchased a combined 507,874 shares of Alumis common stock in open-market transactions at prices ranging from $5.60 to $6.56 per share.
After these transactions, the reporting persons report indirect beneficial ownership of several large blocks of Alumis stock, including 4,247,670 shares held by Foresite Capital Opportunity Fund V, L.P. and 5,584,889 shares held by Foresite Capital Fund VI, L.P., along with additional stakes held by related funds and co-investment vehicles as detailed in the footnotes.
Alumis Inc. (ALMS) director and 10% owner James B. Tananbaum reported multiple open-market purchases of the company’s common stock. On November 17–19, 2025, entities he is associated with bought a total of 507,874 shares at prices ranging from $5.59 to $6.56 per share, increasing his indirect beneficial ownership in Alumis. The shares are held across several Foresite-affiliated investment vehicles, including Foresite Capital Opportunity Fund V, Foresite Capital Fund VI, Foresite Capital Fund V, Labs Co-Invest V, Foresite Labs Fund I and Foresite Labs Affiliates 2021. Tananbaum reports potential voting and dispositive power through these entities but disclaims group status and beneficial ownership beyond his pecuniary interest.
Alumis Inc. (ALMS) director Srinivas Akkaraju reported open-market purchases of Alumis common stock made through affiliated investment funds.
On 11/17/2025, Samsara Opportunity Fund, L.P. bought 914 shares at a weighted average price of $5.51. On 11/18/2025, it purchased 102,652 shares at a weighted average of $6.05, and on 11/19/2025 it bought 137,772 shares at a weighted average of $6.56. After these transactions, the reporting person is deemed to beneficially own 517,517 shares held by Samsara Opportunity Fund, L.P. and 4,491,731 shares held by Samsara BioCapital, L.P., with beneficial ownership disclaimed except for any pecuniary interest.
Alumis Inc. (ALMS) director Srinivas Akkaraju reported an indirect purchase of common stock. On 11/13/2025, 276,179 shares of Alumis common stock were acquired at a price of $5.25 per share in a privately negotiated transaction. The shares were purchased by Samsara Opportunity Fund, L.P. from Samsara BioCapital, L.P., both investment entities with which the reporting person is affiliated.
Following this transaction, 276,179 shares are held through Samsara Opportunity Fund, L.P., and 4,491,731 shares are held through Samsara BioCapital, L.P. The filing notes that the transfer between these entities did not change the reporting person’s overall beneficial ownership, and that he disclaims beneficial ownership in these securities except to the extent of his pecuniary interest.